CanSino Biologics, Inc. Class H (HK:6185)
:6185
Want to see HK:6185 full AI Analyst Report?
Top Page
CanSino Biologics, Inc. Class H
(6185)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$31.00
▼(-31.02% Downside)
Action:ReiteratedDate:04/29/26
The score is held back primarily by weak cash generation (negative free cash flow) and fragile profitability despite recent stabilization, alongside bearish technical signals from trading below key moving averages. Valuation is a major drag due to the extremely high P/E and lack of dividend support, while the balance sheet provides some offset with moderate leverage.
Positive Factors
Moderate leverage and sizable equity
A low debt-to-equity (~0.26) and a sizeable equity base give CanSino structural financial flexibility. This decreases refinancing risk, supports sustained R&D and capacity investments, and cushions the firm against revenue volatility tied to tender cycles or episodic vaccine demand.
Negative Factors
Negative free cash flow persists
Despite improving operating cash flow, persistent negative free cash flow means the company is not yet self-funding capital investment. Ongoing FCF deficits can force external financing, delay strategic investments, or constrain manufacturing scale-up, affecting long-term growth execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate leverage and sizable equity
A low debt-to-equity (~0.26) and a sizeable equity base give CanSino structural financial flexibility. This decreases refinancing risk, supports sustained R&D and capacity investments, and cushions the firm against revenue volatility tied to tender cycles or episodic vaccine demand.
Read all positive factors
CanSino Biologics, Inc. Class H (6185) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.96B
Dividend YieldN/A
Average Volume (3M)609.75K
Price to Earnings (P/E)292.7
Beta (1Y)1.42
Revenue Growth31.39%
EPS Growth98.96%
CountryHK
Employees1,105
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.18
Shares Outstanding132,670,900
10 Day Avg. Volume458,410
30 Day Avg. Volume609,752
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)1.60
Price to Sales (P/S)7.70
P/FCF Ratio-52.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.47
Revenue Forecast (FY)HK$1.43B
CanSino Biologics, Inc. Class H Business Overview & Revenue Model
Company Description
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola vir...
How the Company Makes Money
CanSino Biologics primarily makes money by developing, manufacturing, and selling vaccines. Its revenue model is driven mainly by: (1) Product sales: revenue from supplying marketed vaccines to customers such as government/public health procuremen...
CanSino Biologics, Inc. Class H Financial Statement Overview
Summary
Income Statement
43
Neutral
Balance Sheet
71
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11B | 1.03B | 846.34M | 345.18M | 1.03B | 4.30B |
| Gross Profit | 826.36M | 681.82M | 601.91M | -876.02M | -186.61M | 3.00B |
| EBITDA | -9.45M | 60.98M | -134.84M | -1.65B | -1.32B | 1.85B |
| Net Income | -848.43K | 27.15M | -378.88M | -1.48B | -909.43M | 1.91B |
Balance Sheet | ||||||
| Total Assets | 6.97B | 7.18B | 7.96B | 9.32B | 11.47B | 11.87B |
| Cash, Cash Equivalents and Short-Term Investments | 2.07B | 2.65B | 3.20B | 4.12B | 5.95B | 7.78B |
| Total Debt | 1.16B | 1.29B | 2.01B | 2.70B | 2.70B | 1.37B |
| Total Liabilities | 2.06B | 2.05B | 3.05B | 4.03B | 4.22B | 3.33B |
| Stockholders Equity | 4.91B | 4.96B | 4.91B | 5.27B | 6.75B | 8.00B |
Cash Flow | ||||||
| Free Cash Flow | -137.42M | -152.83M | -626.42M | -1.53B | -2.96B | 811.42M |
| Operating Cash Flow | 71.31M | 32.49M | -168.79M | -916.25M | -1.89B | 2.01B |
| Investing Cash Flow | 683.42M | 355.36M | 3.96M | -449.65M | -1.19B | -2.53B |
| Financing Cash Flow | -855.48M | -703.03M | -334.18M | -7.58M | 854.60M | 1.56B |
CanSino Biologics, Inc. Class H Technical Analysis
Neutral
44.94
Price Trends
33.55
Positive
35.72
Negative
40.76
Negative
Market Momentum
0.21
Negative
58.41
Neutral
90.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6185, the sentiment is Neutral. The current price of 44.94 is above the 20-day moving average (MA) of 33.12, above the 50-day MA of 33.55, and above the 200-day MA of 40.76, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 58.41 is Neutral, neither overbought nor oversold. The STOCH value of 90.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6185.
CanSino Biologics, Inc. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$224.98B | 35.71 | 16.09% | 0.97% | 22.62% | 26.23% | |
72 Outperform | HK$30.45B | 9.36 | 13.95% | 4.09% | 1.48% | -1.55% | |
61 Neutral | HK$32.98B | 6.37 | 7.91% | 2.95% | 4.66% | 20.77% | |
58 Neutral | HK$70.95B | 14.15 | 7.02% | 1.69% | 1.52% | 22.54% | |
56 Neutral | HK$40.18B | 3.39 | 7.89% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$11.96B | 292.71 | -0.02% | ― | 31.39% | 98.96% |
* Healthcare Sector Average
HK:6185
CanSino Biologics, Inc. Class H
29.38
-4.12
-12.30%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
16.71
0.67
4.16%
HK:1513
Livzon Pharmaceutical Group
28.16
3.21
12.86%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
19.11
5.61
41.60%
HK:3320
China Resources Pharmaceutical Group Ltd.
5.25
0.48
10.11%
HK:3692
Hansoh Pharmaceutical Group Company Limited
37.10
12.97
53.75%
CanSino Biologics, Inc. Class H Corporate Events
CanSino Biologics Q1 2026 Revenue Rises but Loss Widens
Apr 28, 2026
CanSino Biologics Inc. reported unaudited results for the first quarter ended March 31, 2026, showing operating revenue of RMB 190.3 million, up 38.7% year-on-year, but a widened net loss attributable to shareholders of RMB 40.4 million. The compa...
CanSino Biologics Tightens Governance With Proposed Articles and Board Rule Changes
Apr 28, 2026
CanSino Biologics Inc. has approved proposed amendments to its Articles of Association and internal rules of procedure, aligning its corporate governance framework with the latest requirements of China’s Company Law and listed company govern...
CanSino Biologics Sets April 28 Board Meeting to Approve Q1 2026 Results
Apr 16, 2026
CanSino Biologics Inc. has scheduled a board meeting for April 28, 2026, to review and approve the company’s first-quarter results for the period ended March 31, 2026. The board will also consider the release of these quarterly figures, sign...
CanSino Wins China Approval for First DTcP Components Infant Vaccine
Apr 12, 2026
CanSino Biologics has received approval from China’s National Medical Products Administration for its DTcP Infant vaccine, a diphtheria, tetanus and acellular pertussis (three components) combined vaccine for children under two, marketed as ...
CanSino Biologics Publishes Audited 2025 Annual Results and Readies Full Report
Mar 30, 2026
CanSino Biologics Inc. has released its audited consolidated annual results for the year ended December 31, 2025, fulfilling disclosure requirements of the Hong Kong Stock Exchange for preliminary annual results announcements. The full annual repo...
CanSino Biologics Sets March 30 Board Meeting to Approve 2025 Results
Mar 17, 2026
CanSino Biologics Inc. has scheduled a board meeting for March 30, 2026 to review and approve the annual financial results of the company and its subsidiaries for the year ended December 31, 2025. The board will also consider the publication of th...
CanSino Biologics Wins PIC/S GMP Nod for Key Conjugate Vaccines
Mar 5, 2026
CanSino Biologics Inc. has obtained a Good Manufacturing Practice certificate under the Pharmaceutical Inspection Co-Operation Scheme for the manufacturing site of its ACYW135 meningococcal conjugate vaccine and 13-valent pneumococcal conjugate va...
CanSino Biologics Swings to Preliminary 2025 Profit on Higher Revenue
Feb 26, 2026
CanSino Biologics reported preliminary 2025 figures showing total revenue of about RMB1.07 billion, up 26.18% year on year, and a swing to net profit attributable to shareholders of roughly RMB27.87 million from a significant loss a year earlier. ...
CanSino Wins China Nod to Extend Use of Menhycia Pediatric Vaccine
Feb 24, 2026
CanSino Biologics Inc. has received approval from China’s National Medical Products Administration for a supplemental drug application expanding the age indication of its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, Menhycia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.